140 related articles for article (PubMed ID: 36242772)
1. The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study.
R Nagler A; Horwitz LI; Jones S; Petrilli CM; Iturrate E; Lighter JL; Phillips M; Bosworth BP; Polsky B; Volpicelli FM; Dapkins I; Viswanathan A; François F; Kalkut G
Am J Health Syst Pharm; 2022 Dec; 79(24):2222-2229. PubMed ID: 36242772
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of different monoclonal antibody regimens among non-hospitalised patients with mild to moderate COVID-19 at high risk for disease progression: a prospective cohort study.
Savoldi A; Morra M; De Nardo P; Cattelan AM; Mirandola M; Manfrin V; Scotton P; Giordani MT; Brollo L; Panese S; Lanzafame M; Scroccaro G; Berkell M; Lippi G; Konnova A; Smet M; Malhotra-Kumar S; Kumar-Singh S; Tacconelli E;
Eur J Clin Microbiol Infect Dis; 2022 Jul; 41(7):1065-1076. PubMed ID: 35727429
[TBL] [Abstract][Full Text] [Related]
3. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Huang DT; McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Nakayama A; Zapf RL; Kip PL; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Seymour CW
JAMA Netw Open; 2022 Jul; 5(7):e2220957. PubMed ID: 35834252
[TBL] [Abstract][Full Text] [Related]
6. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
7. Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
McCreary EK; Bariola JR; Wadas RJ; Shovel JA; Wisniewski MK; Adam M; Albin D; Minnier T; Schmidhofer M; Meyers R; Marroquin OC; Collins K; Garrard W; Berry LR; Berry S; Crawford AM; McGlothlin A; Linstrum K; Nakayama A; Montgomery SK; Snyder GM; Yealy DM; Angus DC; Kip PL; Seymour CW; Huang DT; Kip KE
JAMA Netw Open; 2022 Apr; 5(4):e226920. PubMed ID: 35412625
[TBL] [Abstract][Full Text] [Related]
8. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG
Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124
[TBL] [Abstract][Full Text] [Related]
9. Real-world evaluation of the impact of two anti-SARS-CoV-2 monoclonal antibody regimens on COVID-19 hospitalizations in older adults.
Sobolewski KA; Smoke SM; Brophy A; Vassallo AV; Chen B; Hilden P; Patterson R; Pittiglio M; Raja K; Handler E; Freer C
J Med Virol; 2022 Jun; 94(6):2493-2499. PubMed ID: 35199356
[TBL] [Abstract][Full Text] [Related]
10. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
[TBL] [Abstract][Full Text] [Related]
11. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.
Knopp BW; Weiss HZ; Fahmy S; Goldstein E; Parmar J
Cureus; 2023 Aug; 15(8):e43094. PubMed ID: 37680398
[TBL] [Abstract][Full Text] [Related]
13. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
14. Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
O'Horo J; Challener DW; Anderson RJ; Arndt RF; Ausman SE; Hall ST; Heyliger A; Kennedy BD; Sweeten PW; Ganesh R; Razonable RR
Mayo Clin Proc; 2022 May; 97(5):943-950. PubMed ID: 35512884
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern.
Falcone M; Tiseo G; Valoriani B; Barbieri C; Occhineri S; Mazzetti P; Vatteroni ML; Suardi LR; Riccardi N; Pistello M; Tacconi D; Menichetti F
Infect Dis Ther; 2021 Dec; 10(4):2479-2488. PubMed ID: 34435337
[TBL] [Abstract][Full Text] [Related]
16. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.
Mazzotta V; Cozzi-Lepri A; Colavita F; Lanini S; Rosati S; Lalle E; Mastrorosa I; Cimaglia C; Vergori A; Bevilacqua N; Lapa D; Mariano A; Bettini A; Agrati C; Piselli P; Girardi E; Castilletti C; Garbuglia AR; Vaia F; Nicastri E; Antinori A
Front Immunol; 2022; 13():868020. PubMed ID: 35514955
[TBL] [Abstract][Full Text] [Related]
17. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
[TBL] [Abstract][Full Text] [Related]
19. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study.
Rhudy C; Bochenek S; Thomas J; St James G; Zeltner M; Platt T
Am J Health Syst Pharm; 2023 Jan; 80(3):130-136. PubMed ID: 36264659
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
